CHICAGO, Nov. 14 /PRNewswire-FirstCall/ -- The Female Health Company today announced that it has received an order for four million FC Female Condoms from the Brazilian Ministry of Health. It is anticipated that shipments will begin in early calendar 2008.
Brazil is recognized by UNAIDS and other global public agencies for its highly effective HIV/AIDS prevention, care and treatment programs. The Company is pleased that Brazilian women will continue to have access to the FC Female Condom as a part of Brazil’s outstanding and successful HIV/AIDS programming.
About The Female Health Company, Inc.
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People’s Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.
For more information about the Female Health Company, visit the Company’s web site at http://www.femalehealth.com or http://www.femalecondom.org.
“Safe Harbor” statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company’s current plan and strategies, and reflect the Company’s current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company’s press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company’s operations may vary from those currently anticipated.
CONTACT: William R. Gargiulo, Jr., +1-231-526-1244, Donna Felch,
+1-312-595-9742, both for The Female Health Company
Web site: http://www.femalehealth.com/
